Johnson & Johnson Poised To Win European Approval For Its COVID-19 Vaccine

The European Medical Agency has recommended conditional marketing approval for Johnson & Johnson’s (NYSE: JNJ) single-dose COVID-19 vaccine for those over 18 years of age.

  • The bloc seeks to speed up the sluggish inoculation campaign and boost its supplies of vaccines.
  • The COVID-19 shot is the fourth to be Ok’d for use in the EU after vaccines from Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX), Oxford University / AstraZeneca Plc (NASDAQ: AZN), and Moderna Inc (NASDAQ: MRNA).
  • Also, note that the commission is under pressure for slow vaccine approvals and is reportedly considering emergency approvals as a faster alternative to lengthy conditional marketing authorizations.
  • Price Action: JNJ shares are up 0.7% higher at $160.18 in premarket trading on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralCOVID-19 VaccineEuropean Union
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!